(Q43041150)

English

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

scientific article published on 30 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders (English)

1 reference

Europe PubMed Central

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

1

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

12 November 2017

Shoichi Takahashi

2

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

12 November 2017

Hiromitsu Kumada

10

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

12 November 2017

5

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

12 November 2017

author name string

Joji Toyota

3

1 reference

Europe PubMed Central

12 November 2017

Yoshiyasu Karino

4

1 reference

Europe PubMed Central

12 November 2017

Hiroki Ishikawa

6

1 reference

Europe PubMed Central

12 November 2017

Hideaki Watanabe

7

1 reference

Europe PubMed Central

12 November 2017

Fiona McPhee

8

1 reference

Europe PubMed Central

12 November 2017

Eric Hughes

9

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

30 January 2012

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

55

1 reference

Europe PubMed Central

12 November 2017

3

1 reference

Europe PubMed Central

12 November 2017

742-748

1 reference

Europe PubMed Central

12 November 2017

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

The global health burden of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

21 January 2018

New therapies for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

7 January 2021

based on heuristic

inferred from DOI database lookup

Cefotiam hexetil

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24724

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24724

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43041150&oldid=1978323208"